KUALA LUMPUR/SINGAPORE (Reuters) - China’s Sinovac Biotech defended the safety and efficacy of its experimental COVID-19 vaccine on Wednesday, after researchers in Brazil released late-stage clinical data showing efficacy that was much lower than initially announced.
The vaccine was just 50.4% effective at preventing symptomatic infections in the Brazilian trial, including data on “very mild” cases, researchers said on Tuesday.
Last week, they said the vaccine, called CoronaVac, showed 78% efficacy against “mild-to-severe” cases.
The news prompted Malaysia and Singapore, which have purchase agreements with Sinovac, to say on Wednesday that they would seek more data from the Chinese firm on efficacy rates before they approved and bought supplies.
“These Phase III clinical trial results are sufficient to prove that CoronaVac vaccine’s safety and effectiveness are good around the world,” Sinovac Biotech Chairman Yin Weidong told a news conference.
Different countries used vaccines from the same batch in their trials, but the countries don’t have identical testing protocols, he said.
Piecemeal disclosures from Sinovac’s trials as well as those from studies of other Chinese vaccines have raised concerns that they are not subject to the same public scrutiny as U.S. and European alternatives.
The data from Brazil was released just as Indonesia rolled its vaccination campaign, with President Joko Widodo being the first to be inoculated with Sinovac’s CoronaVac.
Malaysia said on Wednesday it would only go ahead with procurement if the vaccine satisfied the safety and efficacy standards of local regulators.
On Tuesday, Malaysia’s Pharmaniaga Bhd signed a deal with Sinovac to purchase 14 million doses of CoronaVac and later to manufacture it domestically.
Singapore, the only high-income nation with which Sinovac has struck a deal, said it would go through official data when Sinovac releases it, rather than depending on efficacy reported so far, and then decide whether to approve it.
Thailand, which has ordered 2 million doses of CoronaVac said it was still on track to receive and administer the vaccine starting next month, but added it would ask for information directly from Sinovac.
Reporting by Joseph Sipalan in Kuala Lumpur, Chayut Setboonsarng and Panarat Thepgumpanat in Bangkok, Stanley Widianto in Jakarta, Roxanne Liu and Yew Lun Tian in Beijing, Chen Lin in Singapore; Writing by Sayantani Ghosh; Editing by Ed Davies and Mark Potter
Our Standards: The Thomson Reuters Trust Principles.